Skip to main content

Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).

Publication ,  Conference
Sampson, JH; Vlahovic, G; Desjardins, A; Friedman, HS; Baehring, JM; Hafler, D; Rollin, L; Coric, V; Perez, SN; Reardon, DA
Published in: Journal of Clinical Oncology
May 20, 2014

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

TPS2101 / TPS2101

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Sampson, J. H., Vlahovic, G., Desjardins, A., Friedman, H. S., Baehring, J. M., Hafler, D., … Reardon, D. A. (2014). Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). In Journal of Clinical Oncology (Vol. 32, pp. TPS2101–TPS2101). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101
Sampson, John Howard, Gordana Vlahovic, Annick Desjardins, Henry S. Friedman, Joachim M. Baehring, David Hafler, Linda Rollin, Vlad Coric, Susan N. Perez, and David A. Reardon. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).” In Journal of Clinical Oncology, 32:TPS2101–TPS2101. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.tps2101.
Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, et al. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS2101–TPS2101.
Sampson, John Howard, et al. “Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM).Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. TPS2101–TPS2101. Crossref, doi:10.1200/jco.2014.32.15_suppl.tps2101.
Sampson JH, Vlahovic G, Desjardins A, Friedman HS, Baehring JM, Hafler D, Rollin L, Coric V, Perez SN, Reardon DA. Randomized phase IIb study of nivolumab (anti-PD-1; BMS-936558, ONO-4538) alone or in combination with ipilimumab versus bevacizumab in patients (pts) with recurrent glioblastoma (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. TPS2101–TPS2101.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

May 20, 2014

Volume

32

Issue

15_suppl

Start / End Page

TPS2101 / TPS2101

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences